![Antipsychotic Withdrawal Syndrome - Understanding the Hyperbolic Curve and Tapering Antipsychotic Treatment to Reduce the Risk of Relapse Antipsychotic Withdrawal Syndrome - Understanding the Hyperbolic Curve and Tapering Antipsychotic Treatment to Reduce the Risk of Relapse](https://psychscenehub.com/wp-content/uploads/2021/10/How-not-to-switch-antipsychotics-1.png)
Antipsychotic Withdrawal Syndrome - Understanding the Hyperbolic Curve and Tapering Antipsychotic Treatment to Reduce the Risk of Relapse
![Antipsychotic Withdrawal Syndrome - Understanding the Hyperbolic Curve and Tapering Antipsychotic Treatment to Reduce the Risk of Relapse Antipsychotic Withdrawal Syndrome - Understanding the Hyperbolic Curve and Tapering Antipsychotic Treatment to Reduce the Risk of Relapse](https://psychscenehub.com/wp-content/uploads/2021/10/Clozapine-Doses-and-D2-receptor-occupancies-.png)
Antipsychotic Withdrawal Syndrome - Understanding the Hyperbolic Curve and Tapering Antipsychotic Treatment to Reduce the Risk of Relapse
![Chouinard, 2017 Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy - From journals and scientific sources - Surviving Antidepressants Chouinard, 2017 Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy - From journals and scientific sources - Surviving Antidepressants](https://content.invisioncic.com/r138344/monthly_2018_01/image.png.5520a287d2e550469543d9dc290c909e.png)
Chouinard, 2017 Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy - From journals and scientific sources - Surviving Antidepressants
![Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. - Abstract - Europe PMC Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. - Abstract - Europe PMC](https://europepmc.org/articles/PMC7425303/bin/fcz025f7.jpg)
Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. - Abstract - Europe PMC
![IJMS | Free Full-Text | Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia IJMS | Free Full-Text | Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia](https://www.mdpi.com/ijms/ijms-16-26228/article_deploy/html/images/ijms-16-26228-g004.png)
IJMS | Free Full-Text | Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia
![Pharmaceuticals | Free Full-Text | Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics | HTML Pharmaceuticals | Free Full-Text | Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-14-00246/article_deploy/html/images/pharmaceuticals-14-00246-g002-550.jpg)
Pharmaceuticals | Free Full-Text | Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics | HTML
![Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus | CNS Spectrums | Cambridge Core Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20190607063452442-0543:S1092852918001359:S1092852918001359_tab6.gif?pub-status=live)
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus | CNS Spectrums | Cambridge Core
![Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice | Semantic Scholar Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7907fe251390b34170afa3a0a36a0a91c1dc4bb4/4-Figure1-1.png)
Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice | Semantic Scholar
![Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine | BMJ Case Reports Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine | BMJ Case Reports](https://casereports.bmj.com/content/bmjcr/14/4/e242495/F1.large.jpg)
Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine | BMJ Case Reports
![Psychiatric hospitalization following antipsychotic medication cessation in first episode psychosis - Joseph F Hayes, David PJ Osborn, Andreas Lundin, Christina Dalman, 2019 Psychiatric hospitalization following antipsychotic medication cessation in first episode psychosis - Joseph F Hayes, David PJ Osborn, Andreas Lundin, Christina Dalman, 2019](https://journals.sagepub.com/cms/10.1177/0269881119827883/asset/images/large/10.1177_0269881119827883-fig1.jpeg)
Psychiatric hospitalization following antipsychotic medication cessation in first episode psychosis - Joseph F Hayes, David PJ Osborn, Andreas Lundin, Christina Dalman, 2019
![The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research | Schizophrenia The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research | Schizophrenia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41537-019-0090-z/MediaObjects/41537_2019_90_Fig1_HTML.png)